President Donald Trump and U.S. Health and Human Services Secretary Robert F. Kennedy, Jr. have taken a significant leap forward in the battle against the rise in autism spectrum disorder (ASD), developing a multi-pronged strategy aimed at providing families with new treatment options and expanding research. According to a recent statement obtained by HHS.gov, the incidence of ASD has climbed a staggering 400% since 2000, now affecting 1 in 31 American children.
Newly sanctioned by the FDA, leucovorin is poised to soon become the first recognized medication to specifically address speech-related deficits in children with ASD who also suffer from cerebral folate deficiency. This announcement was accompanied by plans to confirm Medicaid coverage for the drug when used for ASD, thereby greatly increasing accessibility. “Today, we are taking bold action—opening the door to the first FDA-recognized treatment pathway, informing doctors and families about potential risks, and investing in groundbreaking research. We will follow the science, restore trust, and deliver hope to millions of American families,” Secretary Kennedy was quoted as saying on HHS.gov.
In addition to the FDA-approved leucovorin label change, Health and Human Services is tackling the usage of acetaminophen during pregnancy with new advisories. Amidst conflicting studies on the drug's safety, physicians are urged to prescribe the lowest effective dose for the shortest necessary duration. The FDA Commissioner Dr. Marty Makary told HHS.gov, “Given the extent of the current autism epidemic, physicians should immediately have this treatment option available for candidate children. We are also sharing new information about the potential risks of acetaminophen so patients can make a more informed decision with their health care provider.”
As part of the overarching initiative, the National Institutes of Health has also unveiled the Autism Data Science Initiative (ADSI), a sweeping $50 million research agenda focusing on the integration of biological, clinical, and behavioral data. This project is unprecedented, using advanced techniques like machine learning and organoid models to explore autism's complex ontology. NIH Director Dr. Jay Bhattacharya expressed to HHS.gov, "Millions of American families who care for autistic kids need scientists to apply gold standard science, expertise, and open minds to figure out how to help these kids."
